Stable VT: A Malignant Deception

So called ‘Stable VT’ is often a classic, high risk clinical scenario. Stable VT is a diagnostic trap where the patient’s BP looks reassuringly stable, but the electrical substrate is a ticking time bomb. For a clinician, the primary challenge is overcoming the “Stable VT = Non-urgent” impression. Here is a breakdown of why hemodynamic stability is often a false friend in the setting of malignant arrhythmia.

---

1. The Myth of the “Stable” Rhythm

Hemodynamic stability is a snapshot in time. A patient may maintain a BP of 110/70 during VT due to robust compensatory mechanisms (intact sympathetic tone, preserved EF, or a slower rate), but this does not mitigate the underlying risk.

• Rate vs. Stroke Volume: Even at a rate of 150 bpm, a young or relatively healthy ventricle can maintain cardiac output. However, the loss of atrial kick and the dyssynchronous contraction eventually lead to myocardial fatigue.
• The Threshold of Collapse: Hemodynamic collapse in VT is often sudden, not gradual. As the myocardium becomes ischemic from the tachycardia, the “stability” can evaporate in seconds, transitioning into VF.

2. Morphological Clues

When the patient is talking to you but the monitor shows a wide-complex tachycardia, the temptation is to call it “SVT with aberrancy.” This is where the Vereckei or Brugada algorithms become vital.

• AV Dissociation: The presence of P-waves marching independently of the QRS is pathognomonic for VT.
• Capture and Fusion Beats: These are important pointers to VT, proving that the ventricles are being activated from a focus within the chamber.
• Concordance: If all precordial leads (V1–V6) are either entirely positive or entirely negative, it is almost certainly VT.

3. Why “Malignant” Still Applies

Stability does not change the substrate. If the VT is occurring in the setting of a scarred myocardium (prior MI) or an ion channelopathy, the electrical instability remains “malignant.”

• R-on-T Phenomenon: Even a currently stable VT can be interrupted by a premature ventricular contraction from another focus, triggering a descent into ventricular fibrillation.
• Troponin Leak: Sustained VT, even if stable, causes subendocardial ischemia, further lowering the threshold for more lethal arrhythmias.

4. The Clinical Trap: Misdiagnosis

The most dangerous mistake is treating “Stable VT” as SVT with a calcium channel blocker (like Verapamil). In VT, Verapamil can cause profound vasodilation and cardiovascular collapse, turning a stable patient into a code blue. An exception is fascicular verapamil responsive VT, often called Belhassen tachycardia.

Clinical Rule of Thumb: In a wide-complex tachycardia, if the diagnosis is in doubt, treat it as VT.

Key Differentiators for Malignant VT

Feature	VT (More Likely)	SVT with Aberrancy (Less Likely)
QRS Width	> 140ms (RBBB) or > 160ms (LBBB)	Usually narrower
Axis	Extreme Right (“Northwest”) Axis	Normal or Left Axis
Response to Adenosine	No effect (usually)	Conversion or slowing
Structural Heart Disease	History of MI/Low EF	Often absent